Trials / Conditions / Large Cell Neuroendocrine Carcinoma of the Lung

Large Cell Neuroendocrine Carcinoma of the Lung

11 registered clinical trials studyying Large Cell Neuroendocrine Carcinoma of the Lung — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC NCT07510594	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727	Novartis Pharmaceuticals	Phase 1
Recruiting	Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors NCT06814496	University of Arizona	Phase 1 / Phase 2
Recruiting	Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Re NCT06736418	Abdera Therapeutics Inc.	Phase 1
Recruiting	FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum NCT06393816	Centre Leon Berard	Phase 2
Active Not Recruiting	DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer NCT05680922	Legend Biotech USA Inc	Phase 1
Active Not Recruiting	A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine NCT05470595	Technische Universität Dresden	Phase 2
Active Not Recruiting	Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC NCT04010357	Case Comprehensive Cancer Center	Phase 2
Withdrawn	Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroe NCT03901378	Ochsner Health System	Phase 2
Completed	Atezolizumab in Large Cell Neuroendocrine Carcinoma NCT06049966	Oncology Center of Biochemical Education And Research	Phase 1
Unknown	uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and L NCT02755675	Rigshospitalet, Denmark	Phase 2